Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 + pembrolizumab versus pembrolizumab first-line trial in PD-L1-high metastatic NSCLC
ChiCTR2400083440Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-2870 + pembrolizumab with Pembrolizumab (2 arms). Primary endpoint: Overall survival. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083440.